asmaa I. ahmed

Dr. asmaa I. ahmed


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
AAasmaa I. ahmed
asmaa I. ahmed
EAEman Moftah Awad
Eman Moftah Awad
NENashwa Fathy Gamal El-Tahawy
Nashwa Fathy Gamal El-Tahawy
AEAzza Ali Kamel El-Sheikh
Azza Ali Kamel El-Sheikh
SWShaimaa Waz
Shaimaa Waz
The anticancer drug methotrexate (MTX) is known to cause hepatotoxicity as a possibly fatal adverse effect that hinders its clinical application. Although the natural flavonoid, dihydromyricetin (DHM), has antioxidant and anti-inflammatory effects; its role against MTX-induced hepatotoxicity has not been explored yet. For this, rats were administrated DHM orally for two weeks at a dose of 300 mg/kg per day, with or without a single i.p. injection of 40 mg/kg MTX on the 9th day of the experiment. MTX caused deterioration in liver structure and function, depicted by an increase in liver enzymes; ALT and AST. Moreover, MTX induced oxidative stress, shown by increasing malondialdehyde and decreasing reduced glutathione and total antioxidant capacity, initiated the inflammatory response via upregulated expression of Toll-like receptor 4 (TLR4) and its downstream transcription factor, nuclear factor-kappa B (NF-κB p65). Consequent to TLR4 signaling cascade, Nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammosome was activated and caused caspase 1 mediated transformation of proinflammatory cytokines interleukin 1β (IL-1β) and interleukin 18 (IL-18) into their active forms. Interestingly, administering DHM with MTX improved liver structure and function, as well as significantly decreased all oxidative stress and inflammatory signaling. Collectively, DHM possesses antioxidant and anti-inflammatory properties that can ameliorate MTX-induced hepatotoxicity, through down-regulation of liver TLR4/NF-κB and therefore prohibit activation of NLRP3/caspase 1 pathway.

11 June 2022 in Environmental Toxicology and Pharmacology
Verified
Journal Article
Closed access
SBSandy R. Botros
Sandy R. Botros
AAasmaa I. ahmed
asmaa I. ahmed
AAAliaa Anter
Aliaa Anter
MKMohamed M.A. Khalifa
Mohamed M.A. Khalifa
Gehan Hussein HeebaGehan Hussein Heeba
Gehan Hussein Heeba

23 March 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AAasmaa I. ahmed
asmaa I. ahmed
EAEman Moftah Awad
Eman Moftah Awad
NENashwa Fathy Gamal El-Tahawy
Nashwa Fathy Gamal El-Tahawy
AEAzza Ali Kamel El-Sheikh
Azza Ali Kamel El-Sheikh
AFAliaa Fath
Aliaa Fath
Background: Methotrexate (MTX) is an effective anticancer, anti-inflammatory, and immunomodulatory agent. However, it induces a serious pneumonitis that leads to irreversible fibrotic lung damage. This study addresses the protective role of the natural flavonoid dihydromyricetin (DHM) against MTX-induced pneumonitis via modulation of Nrf2/NF-κB signaling crosstalk. Methods: Male Wistar rats were divided into 4 groups: control, which received the vehicle; MTX, which received a single MTX (40 mg/kg, i.p) at day 9 of the experiment; (MTX + DHM), which received oral DHM (300 mg/kg) for 14 days and methotrexate (40 mg/kg, i.p) on the 9th day; and DHM, which received DHM (300 mg/kg, p.o) for 14 days. Results: Lung histopathological examination and scoring showed a decline in MTX-induced alveolar epithelial damage and decreased inflammatory cell infiltration by DHM treatment. Further, DHM significantly alleviated the oxidative stress by decreasing MDA while increasing GSH and SOD antioxidant levels. Additionally, DHM suppressed the pulmonary inflammation and fibrosis through decreasing levels of NF-κB, IL-1β, and TGF-β1 while promoting the expression of Nrf2, a positive regulator of antioxidant genes, and its downstream modulator, HO-1. Conclusion: This study identified DHM as a promising therapeutic target against MTX-induced pneumonitis via activation of Nrf2 antioxidant signaling while suppressing the NF-κB mediated inflammatory pathways.

28 November 2023 in Life Sciences
Verified
Journal Article
Closed access
AAasmaa I. ahmed
asmaa I. ahmed
EAEman M. Awad
Eman M. Awad
AMAmr A.K. Mousa
Amr A.K. Mousa
SASara M.N. Abdelhafez
Sara M.N. Abdelhafez
UFUsama A. Fahmy
Usama A. Fahmy
AAAliaa Anter
Aliaa Anter

1 April 2023 in Journal of advanced Biomedical and Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
AAAliaa Anter
Aliaa Anter
EAEman Moftah Awad
Eman Moftah Awad
AKAmr Kamed
Amr Kamed
AAasmaa I. ahmed
asmaa I. ahmed
Gentamicin causes an impairment of vascular function due to endothelial cell damage. Renal injury by gentamicin may contribute to the development of vascular dysfunction due to decreased NO bioavailability as well as increased oxidative stress and inflammation. In this study we investigate the role of DHM on vascular dysfunction induced by gentamicin. Male Wistar rats were divided into 3 groups (n= 6, each); control group; received the vehicle, gentamicin group; given gentamicin (100 mg/kg/day i.p) for 8 days and gentamicin + dihydromyricetin group; rats were treated with dihydromyricetin (200 mg/kg, p.o) concurrently with gentamicin. DHM reversed the GTN-induced histopathological changes of aortic rings. In addition, administration of DHM to GTN treated rats improved the vascular functions evident as enhanced vasorelaxation and vasoconstriction responses to acetylcholine and phenylephrine, respectively. Further, DHM increased the vascular levels of GSH and total antioxidant activity. Immunohistochemical analysis of aortic sections revealed that DHM treatment downregulated NF-κB, TNF-α and caspase-3 expression. Our data provide a new evidence for the protective effects of DHM against gentamicin-induced vascular dysfunction via provoking antioxidant, antiinflammatory and antiapoptotic effects.

27 December 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
SHSara Nabil Hosney
Sara Nabil Hosney
AAasmaa I. ahmed
asmaa I. ahmed
FAFares E. M. Ali
Fares E. M. Ali
Gehan Hussein HeebaGehan Hussein Heeba
Gehan Hussein Heeba
Cisplatin (Cis) has been widely used for treating many types of solid tumors. Despite its clinical effectiveness, Cis has a considerable risk of gonadal damage that may cause infertility. Morin hydrate (MH), a natural bioflavonoid, has been known for its antioxidant and anti-inflammatory effects. Our study aimed to investigate whether pretreatment with MH could protect against Cis-induced testicular toxicity. Thirty-five adult male rats were split into five groups ( n = 7, each); control group received oral 0.5% CMC for 10 days, MH group received oral MH (100 mg/kg) for 10 days, Cis group was given a single dose of Cis (7 mg/kg, i.p) on day 5, (MH 50 + Cis) and (MH 100 + Cis) groups were pretreated with MH (50 mg/kg) and (100 mg/kg), respectively for 5 days before Cis administration, and then, treatment was continued, with either doses, for further 5 days. At the end of the study, blood and testicular tissues were collected for biochemical and histopathological studies. MH administration mitigated the testicular histopathological changes induced by Cis, increased sperm count and motility, and abrogated the abnormalities in sperm morphology. Further, MH enhanced antioxidant status and suppressed the inflammation via downregulating NF-κB and NLRP3 and inflammatory cytokines expression. Our in vitro study revealed that MH enhanced Cis-induced cytotoxicity against cancer cells, including PC3, MCF7, and HepG2. These findings suggested that MH could be applied in Cis chemotherapy regimens as a possible adjuvant therapy to enhance its effect and prevent Cis-induced testicular damage. Graphical